1
|
Chalabi M, Verschoor Y, Van De Haar J, van den Berg J, Kodach L, van Sandick J, van Dieren J, Balduzzi S, Grootscholten M, Veenhof X, Hartemink K, Vollebergh M, Owers E, Bartels-Rutten A, den Hartog-Lievaart P, van Leerdam M, Schumacher T, Haanen J, Voest E. 1219P Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Bakx J, Doeve B, Siersema P, Rosman C, Grieken N, van Berge Henegouwen M, van Sandick J, Verheij M, Bijlsma M, Verhoeven R, van Laarhoven H. PD-1 The impact of COVID-19 on diagnosis, stage and treatment of esophageal and gastric cancer. Ann Oncol 2022. [PMCID: PMC9250150 DOI: 10.1016/j.annonc.2022.04.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Faron M, Cheugoua-Zanetsie M, Thirion P, Tierney J, Cunningham D, Winter K, Fu J, Mauer M, Shapiro J, Burmeister B, Walsh T, Piessen G, Klevebro F, Ychou M, Van Der Gaast A, Law S, Stahl M, van Sandick J, Pignon J, Ducreux M, Michiels S. SO-4 Individual participant data network meta-analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Verheij M, Slagter A, Jansen E, van Laarhoven H, Cats A, van Sandick J, van Grieken N, Muller P, Sikorska K. OC-0107 Randomised phase 2 trial of preop chemo(radio)therapy in gastric cancer: CRITICS-II interim results. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02483-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Slagter A, Vollebergh M, Caspers I, van Sandick J, Sikorska K, Lind P, Nordsmark M, Putter H, Braak J, Meershoek-Klein Kranenbarg E, van de Velde C, Jansen E, Cats A, van Laarhoven H, van Grieken N, Verheij M. OC-0411 The prognostic value of tumor markers in patients with resectable gastric cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06898-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Biesma H, Soeratram A, Sikorska K, Caspers I, van Essen H, Egthuijsen J, Mookhoek A, Hoek D, Vos W, van Laarhoven H, Nordsmark M, van der Peet D, Warmerdam F, Geenen M, Loosveld O, Portielje J, Los M, Kranenbarg EMK, Hartgrink H, van Sandick J, van de Velde C, Verheij M, Cats A, Ylstra B, van Grieken N. Abstract 354: Mucinous phenotype is associated with response to neoadjuvant chemotherapy in microsatellite instable resectable gastric cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Epstein-Barr virus positivity (EBV+) and microsatellite instability (MSI-high) have been shown to be positive prognostic factors for long term survival in resectable gastric cancer (GC) in several studies. However, the benefit of perioperative treatment in patients with MSI-high tumors remains topic of discussion. Here, we present the clinicopathological outcome of patients with EBV+ and MSI-high GCs treated with surgery only in the Dutch D1/D2 trial, and treated with chemotherapy or chemoradiotherapy after preoperative chemotherapy and surgery in the CRITICS trial.
Patients and methods: EBV was determined in tumor tissue using EBV-encoded RNA in situ hybridization (EBER-ISH). PCR and/or immunohistochemistry were performed to determine MSI status. Results were correlated to histopathological response, morphological tumor characteristics and survival.
Results: In the Dutch D1/D2 trial 10.5% (47/447) of tumors were EBV+ and 10.5% (47/447) were MSI-high. In the CRITICS trial 5.5% (25/451) of tumors were EBV+ and 5.5% (25/451) were MSI-high tumors. In the Dutch D1/D2 trial, five-year overall survival probability was 51.1% for EBV+, 46.8% for MSI-high, and 42.5% for EBV-/MSS (P=0.19). In the CRITICS trial, five-year overall survival was 56.0% for EBV+, 47.3% for MSI-high, and 36.5% for EBV-/MSS (P=0.22). In the CRITICS trial, 3 (12.5%) MSI-high tumors showed moderate to complete histopathological response. Interestingly, all three showed a mucinous phenotype. Eight (36.4%) EBV+ and 114 (29.9%) EBV-/MSS tumors showed moderate to complete histopathological response. None of the EBV+ GCs showed mucinous differentiation.
Conclusions: The favorable outcome of GC patients with resectable EBV+ or MSI-high tumors compared to EBV-/MSS tumors remains after perioperative chemotherapy. In MSI-high tumors significant histopathological response to neoadjuvant chemotherapy was found only in those with a mucinous phenotype.
Citation Format: H.D. Biesma, A.T.T.D. Soeratram, K. Sikorska, I.A. Caspers, H.F. van Essen, J.M.P. Egthuijsen, A. Mookhoek, D.M. Hoek, W. Vos, H.W.M. van Laarhoven, M. Nordsmark, D.L. van der Peet, F.A.R.M. Warmerdam, M.M. Geenen, O.J.L. Loosveld, J.E.A. Portielje, M. Los, E. Meershoek - Klein Kranenbarg, H.H. Hartgrink, J. van Sandick, C.J.H. van de Velde, M. Verheij, A. Cats, B. Ylstra, N.C.T. van Grieken, On behalf of the CRITICS investigators. Mucinous phenotype is associated with response to neoadjuvant chemotherapy in microsatellite instable resectable gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 354.
Collapse
Affiliation(s)
- H.D. Biesma
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | - K. Sikorska
- 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - I.A. Caspers
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - H.F. van Essen
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | - A. Mookhoek
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - D.M. Hoek
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - W. Vos
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | | | | | | | | | | | | | - M. Los
- 8St. Antonius Hospital, Nieuwegein, Netherlands
| | | | | | - J. van Sandick
- 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | | | - M. Verheij
- 10Radboud University Medical Center, Nijmegen, Netherlands
| | - A. Cats
- 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - B. Ylstra
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | | |
Collapse
|
7
|
de Steur W, Claassen Y, Hartgrink H, Meershoek Klein Kranenbarg E, van Sandick J, Braak J, Jansen E, van Grieken N, Putter H, Boot H, Cats A, Sikorska K, van Tinteren H, Verheij M, van de Velde C. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer: per protocol analysis of the CRITICS trial. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|